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Digoxin, the cardiac glycoside most frequently used in
clinical practice in the United States, can be given orally
or intravenously and has an excretory half-life of 36 to
48 hours in patients with serum creatinine and blood
urea nitrogen values in the normal range. Since the drug
is excreted predominantly by the kidney, the half-life is
prolonged progressivelywithdiminishing renal function,
reaching about 5 days on average in patients who are
essentially anephric. Serum protein binding of digoxin
is only about 20%, and differs markedly in this regard
from that of digitoxin, which is 97% bound by serum
albumin at usual therapeutic levels. Digitoxin is nearly
completely absorbed from the normal gastrointestinal
tract and has a half-lifeaveraging 5 to 6 days in patients
receiving usual doses irrespective of renal function. The
Pharmacokinetics
Preparations of cardiac glycosides used clinically are de-
rived from the leaves and seeds of plants from the genera
Digitalis and Strophanthus. Other flora contain cardiac gly-
cosides that may be of importance with regard to toxicity,
but are not used clinically. These include Convallaria ma-
jalis (lily of the valley) and Thevetia neriifolia (yellow
oleander) .
All of the cardiac glycosides consist of combinations of
an aglycone, or genin , with one to four attached sugar res-
idues . The characteristic pharmacologic properties reside in
the genin , while factors influencing pharmacokinetic prop-
erties , including water solubility, are influenced by the na-
ture of the sugars (glycosides) attached to the genin.
Figure I outlines the derivation of the cardiac glycosides
currently in clinical use in the United States. Leaves from
the Digitalis lanata plant contain precursor glycosides that
yield digitoxin and digoxin after minor chemical derivation
(1) . The seeds of Strophanthus gratus contain ouabain .
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bioavailability of digoxin is appreciably less than that of
digitoxin, averaging about two-thirds to three-fourths of
the equivalent dose given intravenously in the case of
currently available tablet formulations. Recent studies
have shown that gut ftora of about 10% of patients re-
duce digoxin to a less bioactive dihydro derivative. This
process is sensitive to antibiotic administration, creating
the potential for important interactions among drugs.
Serum or plasma concentrations of digitalis glycosides
can be measured by radioimmunoassay methods that are
now widelyavailable, but knowledgeofserum levelsdoes
not substitute for a sound working knowledge of the
clinical pharmacology of the preparation used and care-
ful patient follow-up.
(J Am Coil Cordial 1985;S:43A-SOA)
Digoxin
Routes of administration. Digoxin is the form of dig-
italis most frequently used in the United States, both in
hospital and office practice. This is probably due in large
part to its flexible routes of administration, its intermediate
duration of action and the availability of convenient methods
for assaying serum digoxin concentrations. Although dig-
oxin may be administered orally , intravenously or intra-
muscularly , the intramuscular route is not recommended
because it is painful and produces localized muscle damage
reflected in increased serum creatine kinase levels . The clas-
sic studies of the pharmacokinetics of digoxin carried out
by Doherty et al. (2) established the patterns observed after
use of these three routes of administration in volunteers with
normal renal function (Fig. 2). As expected, the serum
concentration rises most rapidly after intravenous admin-
istration , followed by oral and , still later , by intramuscular
administration .
Excretion. Excretion of digoxin occurs at a rate inde-
pendent of the route of administration. Digoxin is excreted
in an exponential manner, with an average half-life of 36
hours in healthy individual s with normal renal function (3).
Approximately 37% of total body stores of digoxin are ex-
creted daily under these circumstances. Older patients usu-
ally have a reduced glomerular filtration rate even if the
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Figure 1, Derivation of clinically relevant digitalis
preparations.
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Figure 2. Comparison of pharmacokinetics of digoxin given by
the intravenous (IV), oral and intramuscular (1M) routes. As ex-
pected, serum concentration rises most rapidly by the intravenous
form of administration. T'I2 = half-life of elimination. (Repro-
duced from Doherty et al. [2] withpermission of the authors and
Progress in Cardiovascular Diseases .)
blood urea nitrogen and creatinine levels remain in the nor-
mal range, and a half-life of 48 hours represents a more
reasonable estimate. Renal excretion of digoxin tends to be
independent of the rate of urinary flow in patients with
reasonably normal renal function (4,5). There is, however,
some dependence of renal tubular reabsorption of digoxin
on the urinary flow rate, and hence digoxin reabsorption
ruay increase at very low rates of urinary flow and con-
versely may be decreased by acute vasodilator therapy in
patients with congestive heart failure (6,7). Digoxinexcre-
tion by way of the kidney is predominantly in an unchanged
to.rn, but a subset of about 10% of patients excrete appre-
ciable quantitiesof relatively inactivemetabolites (8). Equi-
librium or steady state conditions occur at the point when
daily losses of digoxin through renal and other pathways
match the daily intake of the drug.
Absorptioh. A useful clinical principle is that when daily
maintenance therapy is begun in patients not previously
receivingdigoxin, steady state plateau concentrations exist
after four to five half-livesor about 7 days in patients with
normal renal function (9). In the presence of renal impair-
mentresulting in prolongation of the half-lifeof elimination,
the time required to reach steady state on a daily mainte-
nance regimen is correspondingly prolonged. When rapid
onset of digoxin effect is needed, a loading dose is admin-
istered. followed by daily maintenance therapy. In obese
subjects, digoxin pharmacokinetics change little after the
loss of large amounts of adipose tissue, indicating that lean
body mass should be used when dosages are calculated
(10,11) .
Nomograms for calculationof the total oral loadingdose
anddaily maintenance doseof digoxinbasedon bodyweight
and renal function are available (12). Such nomograms are
helpful for the initial estimation of digoxin dosage, but do
not change the need for careful follow-up by the clinician.
Gastrointestinal absorption ofdigitalis glycosides is pas-
sive . The rate and completeness of absorption are greatest
with the least polar molecules and decrease with increasing
cardiac glycoside polarity (13). Patients with normal gas-
trointestinal function shouldabsorbdigoxinadministered by
the oral route at about85%of the administered dose in elixir
form and 60 to 75% in tablet formulations that meet current
Food and Drug Administration and United States Pharma-
copeia guidelines (14) (see subsequent comments on
bioavailability).
Protein binding of digoxin averages 20 to 25% under
usualcircumstances (15,16). Only the free fraction is phar-
macologically active. In the caseof digoxin, proteinbinding
is a minor factor in determining the pharmacokinetics be-
cause glomerularfiltration of the drug should be about 80%
of the serum concentration.
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Time course of digoxin distribution in the body. The
time course is well characterized by a two compartment
model (2). Distribution from the central (vascular) com-
partment to peripheral sites occurs with a half-time of about
30 minutes. Although the concentration of digoxin in skel-
etal muscle is relatively low compared with that in the kid-
ney or heart, the total digoxin content of skeletal muscle
represents the largest single pool in the body because of the
large mass of this component of body composition.
Available studies (17) demonstrate a fairly constant ratio
between the digoxin bound to heart muscle and the serum
concentration. It is of importance, however, that electrolyte
derangements can exert clinically significant effects on myo-
cardial uptake and distribution of cardiac glycosides. Hy-
perkalemia and hyponatremia reduce digoxin binding to the
myocardium (4,18). Important interactions among drugs af-
fect the distribution of digoxin in the body, as discussed
elsewhere in this symposium (19).
Absorption and excretion in infants. Infants and chil-
dren usually absorb and excrete digoxin in a manner similar
to that of adults. Nevertheless, digoxin doses in infants
characteristically are larger than those conventionally used
in adults when calculated on the basis of mg/kg of body
weight or per unit of body surface area. These higher doses
tend to produce higher serum digoxin concentrations, which
are usually well tolerated (20-22). Digoxin crosses the pla-
cental barrier, as documented by the observation (20) that
fetal umbilical cord digoxin concentrations are comparable
with those found in the venous blood of the mother at term.
Metabolism of digoxin. Although renal excretion of di-
goxin is the dominant route of elimination, digoxin is me-
tabolized to some degree to reduced compounds such as di-
hydrodigoxin and dihydrodigoxigenin (2). In certain
individuals (about 10% of most patient groups), such me-
tabolism accounts for up to 30 to 40% of the total urinary
excretion of digoxin and its metabolites (8,23). The work
of Lindenbaum et al. (24) established that the metabolism
of digoxin to reduce products varies both with the bio-
availability of the drug and with the nature of the bacterial
flora in the gastrointestinal tract. Consequently, antibiotic
therapy that changes the flora reduces the metabolism of
digoxin to inactive products and can produce an apparent
increase in the effective amount of drug in the body when
the intake of digoxin remains constant. Particular care is
needed in the surveillance of patients receiving digoxin when
antibiotics are added to the regimen. Data regarding the
pharmacokinetics of digoxin and other clinically relevant
glycosides are summarized in Table I.
Digitoxin
Half-life of elimination. Although it is the second most
frequently prescribed cardiac glycoside in the United States,
digitoxin is far less commonly used than digoxin. It is less
polar than any other glycoside in current use and, therefore,
binds avidly to serum proteins. This results in very limited
renal excretion, and the half-life of elimination of digitoxin
accordingly varies littie from the average of 4 to 6 days,
irrespective of renal status (15). Because of the longer half-
life, initiation of daily maintenance doses of digitoxin will
not produce steady state levels until about 3 to 4 weeks.
The bioavailability of digitoxin when administered orally
approaches 100% (25).
As stated, digitoxin binds avidly to human serum albumin
such that about 97% of the drug circulates in a bound state
under usual clinical circumstances. A number of drugs are
reported (26) to displace digitoxin from serum albumin bind-
ing sites, but it is not clear if these interactions are of clinical
importance. It may be that severe depletion of serum al-
bumin (for example, in nephrotic syndrome) may effectively
increase the effect of digitoxin at any given total serum
concentration of the drug.
Mode of elimination. The major route of elimination
of digitoxin is metabolism in the liver. Approximately 8%
of the body digitoxin store undergoes biotransformation to
metabolites, some of which are cardioactive and some of
which are not (27,28). Enterohepatic cycling of digitoxin
averages approximately 6 to 7%/day (29). This cycle can
be interrupted at least in part by nonabsorbable resins, such
as cholestyramine, that bind digitoxin in the gut (30). This
tends to enhance the clearance rate, although it is not Clear
that the effect is sufficient to be decisive in the management
of overt digitoxin toxicity.
Other Cardiac Glycosides
Deslanoside (Cedilanid-D), This glycoside is structur-
ally similar to digoxin, but has an additional glucose residue
attached to the terminal sugar. This results in markedly
decreased gastrointestinal absorption, and deslanoside is used
very little in the United States at the present time. Its ex-
cretion kinetics are very similar to those of digoxin (2).
Ouabain. This is the most polar of the clinically avail-
able cardiac glycosides, and is only used intravenously for
rapid digitalization. It is excreted by exponential or first-
order kinetics, predominantly through the kidney. Patients
with normal renal function have a serum ouabain half-life
averaging 21 hours. As with digoxin, impaired renal func-
tion will slow the excretion of ouabain (31).
Information on the pharmacokinetics of other glycosides
not commonly used in the United States is discussed in
appropriate review articles (17).
Bioavailability
Factors affecting digoxin absorption. Observations in
the 1970s led to the conclusion that some patients had low
serum digoxin concentrations and responded poorly to the
drug despite relatively large oral doses (32). This prompted
the investigation of the bioavailability of several digoxin
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Table 1. Cardiac Glycoside Preparations
Gastroin- Onset of Peak
testinal Action* Effect Average
Agent Absorption (min) (h) Half-Lifet
Ouabain Unreliable 5 to 10 1/2 to 2 21 hours
Deslanoside Unreliable 10 to 30 I to 2
Digoxin 55 to 75%** 15 to 30 IV2 to 5
(Lanoxicaps
90 to 100%)
Digitoxin 90 to 100% 25 to 120 4 to 12
Average Digitalizing
Dose (mg)
Intra-
Oralj venous§
0.10 g
0.10
0.25 to
0.50**
0.5 to
1.5
0.25 to
1.25
0.1 to
0.2
Usual Daily
Oral Mainte-
nance Dose
(rngj]
1.4 to
1.6
1.00
0.80
0.75 to
1.00
0.30 to
0.50
1.25 to
1.50
2.0 to
3.0
6
0.80 to
1.20 g
10
0.70 to
1.20
Principal
Metabolic
Route
(excretory
pathway)
Renal; some
gastrointestinal
excretion
Renal
Renal; some
gastrointestinal
excretion
Hepatictt: renal
excretion of
metabolites
Similar to
digitoxin
Renal
Similar to
digitoxin
Similar to
digitoxin
4 to 6
days
33 hours
36 to 48
hours
4 to 6
days
Similar to
digoxin
4 to 6
days
Similar to
digitoxin
8 to 1020 to 30
About 40%
10 to 40%
About 70%Acetyl-
digitoxin
Digitalis
leaf
Lanatoside C
Gitalintf
* For intravenous dose; t for normal subjects (prolonged by renal impairment with digoxin, ouabain and deslanoside and probably by severe hepatic
disease with digitoxin and digitalis leaf); t divided doses over 12 to 24 hours at intervals of 6 to 8 hours; * given in increments for initial subcomplete
digitalization, to be supplemented by further small increments as necessary; II average for adult patients without renal or hepatic impairment; varies widely
among individual patients and requires close medical supervision; ** for tablet form of administration (may be less in malabsorption syndromes and in
formulations with poor bioavailability). A recently marketed preparation (Lanoxicaps, Burroughs Wellcome Co.) contains digoxin solution in capsules
and has a bioavailability of 90 to 100%. If such a preparation is used, the daily oral maintenance should be reduced by about 20% (for example, Lanoxin
tablets of 0.25 mg and 0.125 mg strengths are approximately equivalent to Lanoxicaps of 0.2 and 0.1 mg strengths, respectively); tt enterohepatic cycle
exists; H Gitalin is a mixture of cardiac glycosides, the principal one of which is digitoxin; *§ approximately 20% lower maintenance doses are required
if gel solution in capsules (Lanoxicaps) is used. (Modified from Smith TW. Drug therapy: digitalis glycosides. N Engl J Med 1973;288:719.)
preparations. Although various pharmaceutical formulations
may contain chemically equivalent amounts of digoxin, studies
(32) have shown a wide range of dissolution rates of avail-
able marketed digoxin tablets from several suppliers. This,
together with individual patient variation, can result in sub-
stantial variability in digoxin bioavailability. Malabsorption
syndromes may also produce poor and erratic digoxin ab-
sorption (33), although maldigestion caused by pancreatic
insufficiency usually results in normal absorption of the
drug. Digoxin ingestion along with or shortly after meals
tends to decrease the peak serum concentration, but total
absorption is not appreciably reduced in patients with normal
gastrointestinal function (34). Digoxin absorption tends to
be enhanced by drugs that reduce the motility of the gas-
trointestinal tract, and conversely can be decreased by drugs
that increase motility (35). Certain nonabsorbable sub-
stances, including cholestyramine, colestipol, kaolin-pectin
and nonabsorbable antacids, can interfere with gastrointes-
tinal absorption of digoxin when taken concurrently (17).
The antibiotic neomycin has also been shown to interfere
with digoxin absorption (36).
Clinical implications. Bioavailability considerations have
important clinical implications given the relatively narrow
margin between therapeutic and toxic digoxin doses and
serum levels. Current FDA and USP bioavailability guide-
lines include defined permissible ranges of tablet dissolution
rates, and require the demonstration in human subjects that
such dissolution rate data translate into clinically reliable
bioavailability (37). Current FDA guidelines require that all
digoxin tablets marketed in the United States must have an
in vitro dissolution rate of at least 65% in I hour, but no
greater than 90% in 15 minutes. Digoxin elixir is more
bioavailable (70 to 85% of the intravenous dose) than the
usual tablet form (60 to 80% of the intravenous dose) (38,39).
A recently marketed digoxin gel solution in capsules (Lan-
oxicaps, Burroughs-Wellcome Co.) has enhanced bioavail-
ability (90 to 100%) compared with tablets, elixir or intra-
muscular preparations. The clinician should be aware that
early high serum digoxin concentrations occur after inges-
tion of the encapsulated gel formulation. Because of the
greater bioavailability, Lanoxicaps of 0.1 and 0.2 mg strength
are approximately equivalent to tablets with a strength of
0.125 and 0.25 mg, respectively.
As emphasized elsewhere in this symposium (19), cli-
nicians must be alert to alterations in the total medication
program of the patient because addition or discontinuation
lACC Vol. 5, No.5
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of a variety of agents, particularly nonabsorbable resins,
antacids or antibiotics, can alter digoxin bioavailability or
the degree of conversion of digoxin to inactive metabolites,
or both.
Serum Digoxin and Digitoxin Concentrations:
Use and Misuse
The problem of the narrow margin between therapeutic
and toxic doses of digitalis has resulted in the development
of various methods to determine serum glycoside levels.
Serum concentration measurements do have clinical value,
but inappropriate use or interpretation of such data limits
their usefulness and can, on occasion, lead to suboptimal
management decisions.
Assay methods. Assay methods currently available have
been reviewed elsewhere (40). Each method has its specific
advantages and disadvantages. The radioimmunoassay tech-
nique (41) is now used in most clinical laboratories . Digoxin
and digitoxin concentrations in serum can be determined
separately given appropriate attention to technical details.
However, radioimmunoassay techniques in general have a
variety of pitfalls, and the clinical usefulness of serum con-
centrations is limited by the accuracy of the reported values.
Proper selection of the antibody population, accuracy of
standards, purity of tracer glycosides and care in the use of
counting methods are all requisite to obtaining satisfactory
results. The presence in serum of diagnostic radioisotopes
used in nuclear medicine scanning techniques can be mis-
leading. In addition, the clinician must avoid drawing blood
samples for cardiac glycoside analysis shortly after doses
so that full equilibration of the drug between the plasma
and the heart and other body compartments is complete.
Sampling of serum should generally be done at least 5 to 6
hours after either oral or intravenous doses.
Rationale for serum digitalis measurements. Several
lines of evidence bear on the relation between serum gly-
coside levels and the corresponding pharmacologic effect.
Both therapeutic and toxic effects of cardiac glycosides are
dose-related. All studies demonstrate that serum glycoside
levels increase with increasing dosage, and a statistical cor-
relation between serum level and clinical state would, there-
fore, be anticipated. Experimental and clinical studies (42,43)
demonstrate a relatively constant ratio of serum to myo-
cardial digoxin concentrations after full equilibration be-
tween vascular and peripheral compartments. Since the car-
diac glycoside binding site of the receptor Na-K adenosine
triphosphatase (ATPase) faces the outer cell surface, a basis
exists for the translation of serum level to effect on the
myocardial cell. Perhaps most importantly, experimental
studies (44) have shown a predictable relation between serum
digoxin concentration and cardiac electrophysiologic effects.
Although true in a general sense, these considerations
leave room for substantial variability in the response of the
individual patient to a given serum digitalis level. The study
of Klein et al. (45), in which serum digoxin levels were
correlated with acetylstrophanthidin tolerance, demonstrated
that severe pulmonary, coronary and aortic valve disease,
as well as old age, predisposed patients to cardiac glycoside
sensitivity. Other variables influencing individual patient
sensitivity to cardiac glycosides are discussed in detail else-
where in this symposium (46).
Clinical correlations of serum digitalis levels.
Approximately 50 studies correlating serum digitalis levels
with clinical state have been published and have been re-
viewed recently (17). These are summarized briefly in Ta-
bles 2 and 3. The findings from these studies, based on data
from more than 1,000 patients, indicate that the serum di-
goxin level in patients receiving therapeutically appropriate
doses averages about 1.4 ng/ml (1.8 nmol/liter), while mean
levels in patients with drug toxicity, as defined by the pres-
ence of typical arrhythmias, are generally higher by a factor
of 2 to 3. Although this difference is statistically significant
in the vast majority of studies, overlap clearly does exist
between serum digoxin levels in groups of patients with and
without toxicity. Such overlap is generally more pronounced
in prospective blind study protocols than in unblinded re-
trospective studies (47).
Extensive data are also available for patients receiving
digitoxin (Table 3). Digitoxin levels in serum or plasma are
higher than those of digoxin by a factor of about 10 because
of substantial serum protein binding of digitoxin as just
discussed. The results of studies of clinical correlations are
otherwise analogous to those for digoxin in that mean levels
observed for groups of patients considered to be optimally
digitalized are significantly less than values for patients with
overt toxicity. Again, substantial overlap exists between
groups with and without toxicity.
In terms of the management of individual patients, I
would emphasize that no specific serum concentration exists
that can be used to define a clear boundary between the
presence and absence of toxicity. A particular problem in
this regard is the definition of digitalis toxicity because
abnormalities of cardiac impulse formation or conduction
resulting from digitalis excess also occur as a consequence
of intrinsic heart disease, even in patients without prior
digitalis exposure. Consequently, serum digitalis levels should
be considered together with all of the additional clinical data
available before a clinical management decision is reached.
Optimal serum glycoside levels. It is no easy matter to
establish optimal serum cardiac glycoside levels, even in
patients with no evidence of toxicity. Chamberlain et al.
(48) observed a correlation, within broad limits, between
serum digoxin concentrations and the ventricular rate in the
presence of atrial fibrillation, at least in patients who had
relatively rapid ventricular rates before administration of
digitalis. It is commonly found that "therapeutic" digoxin
levels are inadequate to control the ventricular rate in acutely
ill patients with problems such as hypoxia, infection or
recent surgery. In the study by Goldman et al. (49), serum
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Table 2. Serumor PlasmaDigoxin Concentrations in Patients
With and Without Toxicity*
Mean Digoxin
Concentration (ng/ml)
Patients Patients
Source Without Toxicity With Toxicity
Aronson et al. 1.60 2.60
Beller et al. 1.00 2.30
Bernabei et al. 1.()O 2.90
Bertler and Redfors] 0.90 2.40
Bertler et al. t 1.40 3.10
Brooker and Jelliffet 1.40 3.10
Burnett and Conklin 1.20 5.70
Ca~thers et aI.' 1.21 2.76
Chamberlain et al. 1.40 3.10
Doering et al. 1.02 3.07
Evered and Chapman 1.38 3.36
Fogelman et aLII 1.40 1.70
Follath et al. 1.20 3.20
Grahame-Smith and Everestt 2.40 5.70
Hayes et al.
Infants 2.80 4.40
Children 1.30 3.40
Hoeschen and Proveda 0.80 to 1.30 2.80
Howard et aLII 0.97 0.91
Huffman et al. 1.49 3.32
Iisalo et al. 1.20 3.10
Johnston et al. 1.00 3.15
Krasula et al.
Infants 1,70 3.60
Children 1.10 2.90
Lader et al. 1.10 2.20
Lehmann et al.
Normokalemic patients NS** 2.73
Hypokalemic patients NS** 1.76
Lichey et al. 1.20 2.50
Loes et al. 1.10 4.90
McCredie et al.
Infants 3.45
Children 1.41 3.81
Morrison et aUt 0.76 3.35
Oliver et al. 1.60 3.00
Park et al. 1.10 3.80
Ritzmann et al. t 1.20 5.50H
Shapiro
Normokalemic patients NS** 3.68
Hypokalemic patients NS** 1.13
Shermann and Bourdon 1.37 4.58
Singh et al. 2.91 4.79
Smith et al. 1.30 3.30
Smith and Haber 1.40 3.70
Suzuki and Ogawa 1.20 3.20
Waldorff and Buch 1.00 2.30
Weissel et al. 1.38 2.97
Whiting et al. 1.40 3.50
Zeegers et al. 1.60 4.40
*Full references to the papers cited are found in reference 17; radioim-
munoassay used in all instances except as noted: trubidium-86 uptake;
tenzymatic displacement; 'adenosine triphosphatase inhibition; 'differ-
ences in mean concentration were statistically significant (p < 0.05) in all
series except as noted; **not stated; ttstatistical significance not stated;
Hmedian concentration.
Table 3. Serumor PlasmaDigitoxin Concentrations in Patients
With and Without Toxicity*
Mean Digitoxin Concentration (ng/ml)
Patients Patients
Source Without Toxicity With Toxicity
Beller et al. t 20.0 34.0
Bentley et al.f 23.0 39.0
Brooker and Jelliffe' 31.8 48.8
Chiche et al.t 25.4 57.0
Dessainrt 26.8 96.0
Hillestad et aLII 16.8 28.3
Lukas and Peterson.. 20.0 43.0 to 67.0
(range)
Morrison and Killipt 25.0 53.0
(0.1 mg/day)
Peters et al. t 28.8 56.4
Rasmussen et aLII 16.6 48.7
Ritzmann et aLII 20.5tt 37.0tt
Smithj 17.0 34.0
*Full references to the papers cited are found in reference 17; tra-
dioimmunoassay; tadenosim; triphosphatase inhibition; 'enzymatic dis-
placement; Ilrubidium-86 uptake; **double isotope dilution derivative;
ttmedian concentration.
digoxin levels of +.5 ng/ml or greater were required to
control the ventricular response in 15 of 39 patients. The
current availability of beta-adrenergic blocking agents and
verapamil usually obviates the need for the use of unusually
large doses of digitalis to control the ventricular response
in the presence of supraventricular tachyarrhythmias.
A particularly difficult question relates to the definition
of optimal serum glycoside concentrations ill patients with
congestive heart failure and normal sinus rhythm. Although
the available data are somewhat limited, recent studies (17)
suggest that the favorable hemodynamic effects of digoxin
may tend ~o plateau at serum levels in the range of 1.0 to
1.5 ng/rnl. It remains to be shown whether higher, serum
levels will produce further enhancement of the contractile
state. Thus, it may well be that the optimal risk-benefit ratio
is achieved at serum levels in the 1.0 to 1.5 range. There
is certainly no doubt that higher levels expose the patient
to an increased risk of cardiac glycoside-induced rhythm
disturbances.
Cost-effectiveness. The cost-effectiveclinical use of serum
glycoside measurements, as with all laboratory tests, re-
quires considerable sophistication on the part of the clini-
cian. Evaluation of timing and magnitude of prior digoxin
doses, renal function and body mass allows a first approx-
imation of the body stores of the drug. When patients re-
ceiving maintenance digitalis develop symptoms such as
fatigue, visual changes, anorexia, nausea, vomiting or car-
diac arrhythmias, digitalis intoxication should be suspected
and serum level data are likely to be of use. Serum digoxin
levels within the range usually considered as "therapeutic"
JACCVol. 5. No.5
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should not be considered to exclude toxicity in view of the
marked variability in individual patient responses. The na-
ture and severity of underlying heartdisease are particularly
important variables.
Failure to achieve adequate therapeutic response.
Another common clinical problem is the failure to achieve
an adequate therapeutic response in a patient receiving con-
ventional digoxin doses. It must be determined whether the
dose is inadequate (for example, as a result of impaired
gastrointestinal absorption or noncompliance with a pre-
scribed regimen) or whether there are reasons why the pa-
tient may be relatively resistant to usual digoxin doses and
serum levels (for example, occult thyrotoxicosis or mitral
stenosis). If the patient is taking the prescribed dose and
the serumdigoxin level remains low, this information may
provide the clue to other clinical disorders or drug inter-
actions. Hyperthyroidism tends to produce relatively low
serum digoxin concentrations in addition to true resistance
to control of the ventricular response to atrial fibrillation
typical of this condition. Malabsorption syndromes andpoorly
bioavailable digoxin preparations will result in low serum
digoxin concentrations and clinical signsof inadequate dig-
italization. Drug interactions, as discussed elsewhere (19),
can produce substantial variations in serum levels.
Lastly, skepticism is appropriate when laboratory results
conflict with clinical judgment. Underno circumstances can
serum digitalis levels replace sound clinical judgment. In-
dividual laboratory values should never be used as the sole
basis for determining the presence of drug toxicity or effi-
cacy. I do not advocate the periodic routine measurement
of serumdigoxin concentrations in patients with a satisfac-
tory therapeutic response to a properly chosen dosage reg-
imen. The best assurance of an optimal risk-benefit ratio
will always be the careful follow-up of the patient by a
vigilant clinician.
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